Neurology

Top Medical News
Onasemnogene abeparvovec for spinal muscular atrophy safe in heavier babies
3 hours ago
Babies who weigh ≥8.5 kg can safely be administered with onasemnogene abeparvovec for the treatment of spinal muscular atrophy, a new study has found.
Cranberries sharpen memory, neural function in healthy seniors
Jairia Dela Cruz, 7 hours ago
Eating a small cup of cranberries daily is apparently good for the brain, enhancing memory consolidation and retrieval for everyday events as well as neural functioning in healthy older adults, as shown in a recent study.
‘1-2-3-4-day rule’: Initiating DOACs according to stroke severity may be the way to go
Jairia Dela Cruz, Yesterday
Following nonvalvular atrial fibrillation (NVAF)-associated stroke events, a graded increase in delay in direct oral anticoagulants (DOACs) initiation of between 1 and 4 days, depending on the severity of the index event, appears to be effective for recurrent stroke prevention and does not compromise safety both in Asians and Europeans, according to a recent study.
Keto diet: Is there good evidence in MS?
Elvira Manzano, Yesterday
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Subjective cognitive decline a red flag for Alzheimer’s disease
2 days ago
Subjective cognitive decline appears to be indicative of stage 2 Alzheimer’s disease, where individuals exhibit mild changes in mood or behaviour and subtle objective cognitive decline although not to the point of meeting mild cognitive impairment criteria, as suggested in a study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
4 days ago
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Special Reports
Product Highlight - Pontevia
16 Mar 2022
Galcanezumab Injection
Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes
04 May 2018
Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.
Conference Reports
Keto diet: Is there good evidence in MS?
Elvira Manzano, 23 May 2022
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Sustained benefits with ocrelizumab in relapsing-remitting MS
Roshini Claire Anthony, 19 May 2022

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia
Elaine Soliven, 19 May 2022
Patients with Parkinson’s disease dementia (PDD) who continued treatment with pimavanserin had a lower risk of psychosis relapse compared with those on placebo, according to a post hoc analysis of the HARMONY* trial presented at AAN 2022.
No apparent link between COVID-19 vax and cerebrovascular outcomes
Roshini Claire Anthony, 13 May 2022

Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.

How does IV edaravone fare for ALS in the real world?
Audrey Abella, 10 May 2022
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
Ravulizumab shows rapid, sustained benefits for myasthenia gravis
Pearl Toh, 09 May 2022
Treatment with ravulizumab leads to rapid and sustained reductions in myasthenia gravis (MG) symptoms, according to the CHAMPION study presented at AAN 2022.
New data boost efficacy, safety of lower-sodium oxybate for idiopathic hypersomnia
Audrey Abella, 05 May 2022
Lower-sodium oxybate – a new oxybate treatment with 92-percent less sodium than sodium oxybate – continued to demonstrate its potential in improving function, productivity, and sleepiness in individuals with idiopathic hypersomnia, according to data presented at AAN 2022.
Product Highlights
CME Modules